yourstate.us
21 CFR 866.3367

§ 866.3367 Device to detect and identify microbial nucleic acids by FISH in clinical specimens.

United States · 21 CFR — Food and Drugs · Status: effective

Get this as JSONEmbed this
Cite this
Citation
21 CFR 866.3367, § 866.3367 Device to detect and identify microbial nucleic acids by FISH in clinical specimens, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/89534
Permanent ID
ys:prov:89534@1
SHA-256
9019c9263d163504e053c70fafe282da6193b2caa968c9fc220655cd17221396

The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.

Full text

(a) Identification. A device to detect and identify microbial nucleic acids by fluorescence in situ hybridization (FISH) in clinical specimens is an in vitro diagnostic device intended for the detection and identification of microbial pathogens in specimens collected from patients with signs and symptoms of infection. The device is intended to aid in the diagnosis of human disease in conjunction with clinical signs and symptoms and other laboratory findings. (b) Classification. Class II (special controls). The special controls for this device are: (1) Design verification and validation must include the following: (i) Detailed device description documentation, including the device components, instrument requirements, ancillary reagents required but not provided, and a detailed explanation of the methodology, including all pre-analytical methods for processing of specimens, probe sequences, and rationale for probe sequence selection; (ii) Detailed description of the fluorophores, signal source, detection mechanism, and method of result interpretation; (iii) Detailed documentation from the following analytical studies: analytical sensitivity (Limit of Detection), inclusivity, reproducibility, interference, cross reactivity, and specimen stability; and (iv) Detailed documentation from a clinical study that includes prospective (sequential) samples. The study, performed on a study population consistent with the intended use population, must compare the device performance to results obtained from appropriate and well-accepted comparator methods. (2) The labeling required under § 809.10(b) of this chapter must include: (i) A statement that the device is intended to be used in conjunction with clinical history, signs, symptoms, and the results of other diagnostic testing; (ii) A detailed explanation of the interpretation of results and acceptance criteria for any quality control testing; and (iii) A limitation that negative results do not preclude the possibility of infection.

Legislative history

This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.